Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea

NCT03761134 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

377

Enrollment

INDUSTRY

Sponsor class

Stopped Sanofi ended collaboration with Lexicon for Sotagliflozin. In China no regulatory pathway to transfer sponsorship during the conduct of ongoing studies.

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: sotagliflozin (SAR439954)
DRUG: placebo
DRUG: metformin
DRUG: sulfonylurea

Sponsor

Sanofi